Ithaca, NY, Apr 18, 2022 - (ACN Newswire) - Cornell Blockchain Club's 2nd Annual Conference, "Web3 Going Mainstream," is set to kick off Friday, April 22nd at Roosevelt's Island in NYC. The one-day event serves to highlight how Web3 is simultaneously transcending institutional, academic, and corporate spheres.
In attendance will be the world's leading industry professionals, researchers, and firms, including John Wu (President of Ava Labs), Arwin Holmes (EY Global Blockchain CTO), Joe Conyers (Head of NFTs at Crypto.com), Algorand, FTX, Chainalysis, Gemini, Messari, DyDx, and many more.
This year's agenda is split into four parts: DeFi, NFTs, Regulation, and Institutions, which all have a large role to play in "Web3 Going Mainstream."
There is no university blockchain club better to host this event than Cornell's. In 2019, Cornell Blockchain Club hosted their first annual Blockchain conference which was deemed a success after 250+ attendees came to hear Emin Gun Sirer (Founder/CEO of Ava Labs), Sam Cassatt (CSO at Consensys), Kathleen Breitman (Co-Founder of Tezos) and many more speak. In fact, it was such a success that the members got to ring the Nasdaq bell.
Additionally, Cornell University has an extensive history with the development of Web3. Founded in 2017, Cornell Blockchain Club was the nation's first official university blockchain club. Since then, Cornell was named #1 University in the world for Crypto Education in 2019 by Coinbase, has created a semester-long undergraduate class with over 130 students, and has cultivated project teams who have done things like creating a Uniswap Arbitrage Bot and conducting research for the Web3 Foundation.
Cornell Blockchain Club hopes to you bridge the gap at "Web3 Going Mainstream." Follow along and stay updated here: cornellblockconference.com
HONG KONG, Apr 12, 2022 - (ACN Newswire) - Hong Kong Investor Relations Association (HKIRA) is pleased to announce that public nomination is now open for the HKIRA 8th IR Awards 2022 (the 'Awards'). This will be the eighth consecutive year of the Awards at which remarkable practices of good IR and corporate governance are recognized among Hong Kong listed companies.
Professor Louis Cheng, Dr. S H Ho Professor of Banking and Finance and the Director of Research Centre for ESG, The Hang Seng University of Hong Kong, Chairman of the Judging Panel (left) and Dr Eva Chan, Founding Chairman of HKIRA (right).
Dr Eva Chan, Founding Chairman of HKIRA, said, "It has been another challenging year for business operators in most industries. IR professionals' role is increasingly important in keeping investors and the public abreast of the latest update of listed companies and their industries. Under the new normal, new forms of communication channels are supported by advanced technologies, to facilitate instant and transparent exchange of information. We are glad that the IR community was able to turn challenges into opportunities and we look forward to recognizing more listed companies with best practices at this year's Awards."
Last year, 167 award entries were received from listed companies, over 890 eligible voters and over 360 voting institutions participated in the voting, casting a total of more than 7,900 votes. 47 winners from various categories were recognized at the Awards. Among the winners, China Resources Beer (Holdings) Company Limited (stock code: 00291), Fortune Real Estate Investment Trust (stock code: 00778), and Xtep International Holdings Limited (stock code: 01368) were awarded Overall Best IR Company by company size - Large Cap, Mid Cap, and Small Cap - respectively.
The HKIRA 8th IR Awards 2022 is once again honoured to have Professor Louis Cheng, Dr. S H Ho Professor of Banking and Finance and the Director of Research Centre for ESG at, The Hang Seng University of Hong Kong, as the Chairman of the Judging Panel. Being an advocate of IR best practice among Hong Kong listed companies, Professor Cheng has in recent years been researching on how ESG impacts investors' decisions. Observing its increasing importance, ESG-related awards have been added to the HKIRA IR Award categories since 2020. With ESG investing becoming increasingly mainstream in the professional investment community and ESG ratings often being used by investors, Professor Cheng has also been looking into the topic of score divergence (i.e. disagreement) among commercial ESG raters, and how such divergence affects or benefits investors.
Public nomination for the HKIRA 8th IR Awards 2022 is now open to Hong Kong-listed companies. Nominated individuals and companies will be placed on the online voting list upon confirmation of their participation. The investment community, including buy-side and sell-side analysts, and fund managers, are eligible to vote. Nominees with the highest votes (weighted) in each award category become the award winners. They then undergo a final assessment by the judging panel for the Most Progress in IR, the Overall Best IR Company Awards and the Grand ESG Award. Facilitating a fair and balanced evaluation, the judging panel comprises academics, representatives from professional associations and the investment community.
The HKIRA 8th IR Awards 2022 scheme has a total of 15 award categories honouring best IR practices of individuals and companies. Among these awards, 12 categories are open for nomination and voting, while the other 3 awards are selected by the judging panel. The award winners are to be announced at a ceremony to be held in Hong Kong in September 2022. For more information, please visit www.hkira.com/awards.
Strategic Public Relations Group is once again proud to be the Official Public Relations Partner and the Diamond Sponsor for the HKIRA IR Awards this year. Please find key dates relating to the Awards with its categories and criteria for selection listed in the Appendix.
About HKIRA Hong Kong Investor Relations Association (HKIRA) is a non-profit professional association comprising investor relations practitioners and corporate officers responsible for communication between corporate management and the investment community. HKIRA advocates the setting of international standards in IR education, advances the best IR practices and meets the professional development needs of those interested in pursuing the investor relations profession.
HKIRA is dedicated to advancing the practice of IR as well as the professional competency and status of its members. To date, HKIRA has over 1000 members most of whom are working for companies primarily listed on the Stock Exchange of Hong Kong. About 68% of the Hang Seng Index Constituent Stock companies are currently members of HKIRA. HKIRA's members are from a wide spectrum of professions including IR, finance, accounting, company secretarial to corporate investment and hold positions at different corporate levels, including top executives responsible for IR and management of listed companies. For more information about HKIRA details, please visit our website http://www.hkira.com.
About the IR Awards The HKIRA Investor Relations Awards (the "IR Awards") is an annual campaign that aims to encourage, recognize and reward the excellence in investor relations practices by individuals and companies listed in Hong Kong Stock Exchange. Since the launch in 2015, each year the Awards seeks out and highlights the incredible achievements of individuals and companies with high standards in investor relations through their role modelling to the investment community.
The Awards ceremony, consisting of a conference in the morning and presentation in the afternoon, is a spectacular gathering of IR specialists and industry professionals that applauds and publicizes the year's achievements in investor relations. For details of the Awards and online nominations, please visit http://www.hkira.com/awards.
Appendix Key Dates Nomination period: 12 April to 17 May Online voting period: 23 May to 29 June Judging Panel Meeting: July 2022 Award Presentation: September 2022
Award Categories Award Categories / Recognition / Selection Method Best IR Company / Company's Achievements / Open for nomination and online voting Best IR Team / Company's Achievements / Open for nomination and online voting Best ESG (E) / Company's Achievements / Open for nomination and online voting Best ESG (S) / Company's Achievements / Open for nomination and online voting Best ESG (G) / Company's Achievements / Open for nomination and online voting Best Investor Meeting / Company's Achievements / Open for nomination and online voting Best Investor Presentation Material / Company's Achievements / Open for nomination and online voting Best Annual Report / Company's Achievements / Open for nomination and online voting Best IR Company for an IPO* / Company's Achievements / Open for nomination and online voting Best IR by Chairman/CEO / Individual's Achievements / Open for nomination and online voting Best IR by CFO / Individual's Achievements / Open for nomination and online voting Best IRO (Investor Relations Officer) / Individual's Achievements / Open for nomination and online voting Most Progress in IR / Demonstration of the most progress in IR in the above areas during 2021 / Selected by Judging Panel Overall Best IR Company Awards / Outstanding and all-round excellence in the above areas / Selected by Judging Panel Grand ESG Award / Overall excellence in all the three areas across ESG / Selected by Judging Panel
* Companies which were listed on the Stock Exchange of Hong Kong in 2020 and 2021 are eligible to be nominated for this award. Remarks: All awards will be further categorised by company market capitalisation into Large Cap, Mid Cap, and Small Cap, except Best IR Company for an IPO and Most Progress in IR Awards.
Judging Panel (Arranged in alphabetical order of last name) Name Title Firms / Organizations Professor Louis Cheng (Chairman of Judging Panel) / Dr. S H Ho Professor of Banking and Finance, Director of the Research Centre for ESG, Director of the Research Institute for Business / The Hang Seng University of Hong Kong Mrs Amy Donati / Executive Director and Chief Executive Officer / EDICO Holdings Limited Ms Ashley Khoo, CFA, CPA / Past President and Board Director / CFA Society Hong Kong Mr Andrew Look / Independent Non-Executive Director / CITIC Resources Holdings Limited Ms Victoria Mio, CFA, FRM / Head of Equity Research, Asia Pacific / Fidelity International Dr Maurice Ngai / General Committee and the Chairman of Membership Services of the Sub-Committees / Chamber of Hong Kong Listed Companies Mr Wilfred Yiu / Managing Director and Co-Head of Markets / Hong Kong Exchanges and Clearing Limited
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comHong Kong Investor Relations Association (HKIRA) is pleased to announce that public nomination is now open for the HKIRA 8th IR Awards 2022 (the 'Awards').
MADRID, SPAIN, Apr 7, 2022 - (ACN Newswire) - Elk Finance which is a decentralized network for cross-chain liquidity has announced the launch of its ElkNet v2 upgrade. ElkNet v2 is the first fully functional version of the ElkNet protocol, with security and efficiency as its highlighting upgrades.
For more details, please visit Introducing: ElkNet v2 (Overview, Token Migration & Governance) | by Elk.Finance | Elk Finance | Mar, 2022 | Medium https://bit.ly/3ujn9D9
The upcoming ElkNet v2 upgrade will be secured by design with various security checks and transfer limits in place. It will work on a cross-chain triangle model where security, speed, and cost will be balanced within the network to enhance user experience.
Cross-chain messaging is one of the highlighting features of ElkNet v2 which will allow outside developers to deploy cross-chain smart contracts and web3 applications.
ElkNet v2 is a ground-breaking cross-chain architecture based on a system of token "reservoirs" that are installed on each chain supported by ElkNet.
ElkNet Reservoirs will improve transparency, minimize custodial risk, and reduce smart contract vulnerabilities all at the same time.
Another interesting part of the ElkNet v2 upgrade is the deployment of a new ELK token contract which is a pre-requisite to installing the ElkNet Reservoirs. In order to take advantage of the new features and network operations, users must upgrade to ElkNet v2 from the Elk dApp.
As part of the ElkNet v2 upgrade, the first official governance vote will also be initiated. A significantly revised ELK tokenomics framework will be presented to users for approval.
The first vote will be placed during the token upgrade and the token update will be followed by a poll about each of the new token contracts, with the results being published on the blockchain.
Detailed information about the ElkNet v2 upgrade is available in the above-mentioned medium article.
Elk Finance is going to launch its ElkNet v2 upgrade on April 9th, 2022, with upgrades including an ELK token upgrade, first governance vote, ElkNet Reservoir System, and many other updates.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comElk Finance which is a decentralized network for cross-chain liquidity has announced the launch of its ElkNet v2 upgrade. ElkNet v2 is the first fully functional version of the ElkNet protocol, with security and efficiency as its highlighting upgrades.
How Is Crypto Taxed in the United States? It’s important for investors, including those with cryptocurrency IRAs, to understand how taxes affect their accounts. Cryptocurrencies are treated as property according to the IRS, just like many other investments. Every sale may cause a taxable event, with only a few exceptions. But if you hold your […]
HONG KONG, Apr 1, 2022 - (ACN Newswire) - On March 31, the China-based novel vaccines company - Jiangsu Recbio Technology Co., Ltd. ("Recbio" or the "Company", Stock Code: 2179.HK) went public and was officially listed on the Hong Kong Stock Exchange. Assuming the Over-allotment option is not exercised, 30,854,500 H shares were issued under the Global Offering, with a price of HK$24.80 per share and proceeds up to approximately HK$765 million. The Hong Kong public Offering received an enthusiastic response from investors and was over-subscribed by more than 9.65 times. As the cornerstone investors of the Company, the cornerstone subscription ratios of Yangtze River Pharmaceutical, Harvest Global and Sequoia China exceed 50%. Previously, the Company has won the favor of many well-known investment institutions, including Legend Capital, LYFE Capital, Oriental Fortune Capital, Fer-Capital, Sequoia China, CMB International, Lake Bleu and Temasek. Having successfully listed in Hong Kong, becoming "the first HPV vaccine stock in Hong Kong" and "the first novel adjuvant vaccine stock in Hong Kong", Recbio is expected to inject new vitality into the capital market in Hong Kong.
Chart: Innovative vaccine portfolio of Recbio
Domestic vaccine innovation and iteration accelerated by novel adjuvant technology
Vaccines are praised as the "golden track" in the medical health field. According to the Frost & Sullivan report, from 2016 to 2020, the size of the global vaccine market has increased from US$27.5 million to US$39.9 billion at a CAGR of 9.7%, while the CAGR of global pharmaceutical market was only 3.02%. China has become the second largest vaccine market globally, with the market volume increased from RMB27.1 billion in 2016 to RMB75.3 billion in 2020 at a CAGR of 29.1%.
Regarding the insufficient domestic supply of and the unmet urgent demand for novel vaccines, it has become an important part of the Development Planning of the Pharmaceutical Industry in the "14th Five-Year Plan" in China (referred as the "Plan") to promote enterprises to speed up the development of related products and to achieve product availability as soon as possible. Regarding the development of the vaccine industry, the "Plan" also states that research and development of novel vaccines (such as novel adjuvants for vaccines and mRNA vaccines) and building of industrialization capability shall be accelerated. It also emphasizes on the development of novel COVID-19 vaccines, herpes vaccines, polyvalent human papillomavirus (HPV) vaccines and other products.
As an innovative novel vaccine company, Recbio has constructed the three core technology platforms consisting of novel adjuvants, protein engineering and immunological evaluation, forming synergy in antigen design and optimization, adjuvant development and production, identification of the best combination of antigen and adjuvants. The Company has built a comprehensive and high-valued vaccine portfolio consisting of 12 candidates, covering cervical cancer, COVID-19, adult tuberculosis, shingles, HFMD, influenza etc. It covers five of the ten diseases with the greatest burden under the 2019 Global Burden of Diseases issued by the World Health Organization and disease areas of the three of the top five globally bestselling vaccine products in 2020.
Novel adjuvant for vaccines is the "bottleneck" technology of innovative vaccines. Through years of technical research, Recbio has successfully achieved independent control of all FDA-approved novel adjuvants, and is one of the few companies in the world capable of independent development of novel adjuvants. It has also successfully applied in various innovative vaccines such as COVID-19 vaccines, HPV vaccines and shingles vaccines.
A moat constructed with a rich product portfolio
HPV vaccines are one of the most commercially valuable vaccines in the world. It is expected that there will be 234 million females in China aged 9-45 unvaccinated for HPV in 2025 assuming 3 doses per person, requiring additional 702 million doses. Currently, Recbio has formed a full coverage of bivalent, quadrivalent and 9-valent vaccines and novel adjuvant upgrades in the field of HPV vaccines. The core product REC603, a recombinant HPV 9-valent vaccine is currently under phase III clinical trial, expected to become the first approved domestic HPV 9-valent vaccine. Regarding the global immunization program market, REC601, a bivalent vaccine has the potential to become one of the most popular vaccine options. At the same time, the Company is also in the process of developing second-generation HPV vaccines, namely REC604a (a quadrivalent vaccine) and REC604b (a 9-valent vaccine). Both vaccines have adopted our self-developed novel adjuvants and are expected to achieve two-shot regimens in the future. The construction of the first phase of the HPV manufacturing facility of Recbio is expected to be completed by the end of this year. By then, it will realize the designed capacity of five million doses of HPV 9-valent vaccines or 30 million doses of HPV bivalent vaccines per year. As the first cancer preventive vaccine in the world, HPV vaccines have been in shortage for a long time. With the gradual release of domestic HPV vaccines in the future and the gradual release of production capacity, domestic substitution will be accelerated.
Protein engineering, novel adjuvant and other technology are comprehensively used in ReCOV, the COVID-19 vaccine of Recbio, to thoroughly optimize the vaccine, allowing ReCOV to possess a series of comprehensive advantages, including excellent safety, strong immunogenicity, strong cross-protection effectiveness with Omicron and Delta mutant strains, easy-to-scale-up production, low production cost, high preparation stability, storage and transportation in room temperature etc. The international phase II/III clinical trials of such vaccine are currently in progress. EUA/BLA applications are estimated to be submitted in 2022. On the side of production supply, the Company has completed the construction of our GMP-standard manufacturing facility for ReCOV and obtained the drug production license in November 2021. The manufacturing facility has a total GFA of approximately 17,000 sq.m., has the potential to support an annual manufacturing capacity of 300 million doses of ReCOV and can be used to manufacture recombinant shingles vaccines.
In the field of shingles vaccines, shingles virus is dormant in almost all adults over 50 of age in China, affecting approximately 2.5 million adults in China every year. However, Shingrix is currently the only shingles vaccine approved in China. The novel adjuvant which benchmarking AS01 is adopted in REC610 of the Company, significantly improving vaccine immunogenicity, hoping to achieve domestic substitution quickly.
Recogen, our subsidiary has first achieved technology breakthrough in lyophilized mRNA vaccines. It has applied the self-developed freeze-drying technology to achieve preparation stability at 4 degrees Celsius and 25 degrees Celsius, allowing storage and transportation under general cold-chain conditions, effectively solving the current defect in availability of mRNA vaccines.
"We are glad that the Hong Kong stock IPO has been highly recognized by the capital market. The successful listing of Recbio is expected to bring more confidence to the Hong Kong 18A stock market. Thanks to all the investors for their strong support, we were able to successfully go public as originally planned in such extremely depressed environment of the Hong Kong capital market!" Regarding the listing of Recbio in Hong Kong, Dr. Liu Yong, the Founder, Chairman of the Board, and General Manager of Recbio stated that, "Against the backdrop of a huge global demand for innovative vaccines in this era, through continuous innovation and international cooperation, we will accelerate the commercialization of products in the global market, promote innovation in the entire value chain of the vaccine industry from R&D to commercialization, and create greater value for shareholders and investors. Today is the beginning of a brand-new journey for Recbio. I hope that all investors will continue to support our Company. Let's hope we will continue to move forward hand in hand, through the sweltering summer and winter, and create new glory together!"
About Recbio Founded in 2012, Recbio is an innovative vaccine company with independent research and development technology as its core driving force. It is committed to building a full value chain of innovative vaccines, covering research and development, production and commercialization. The Company has always adhered to the mission of "creating first-class vaccines and protecting human health". With a strong research and development engine comprising of novel adjuvants, protein engineering, immunological evaluation and other core technology platforms, strategically focusing on disease areas with significant burden such as cervical cancers COVID-19, shingles, adult TB, HFMD and flu etc., the Company has established a high-value product pipeline consisting of 12 vaccine candidates with independent intellectual property rights, in order to meet the under-fulfilled public health needs. For more information, please visit https://www.recbio.cn/.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comOn March 31, the China-based novel vaccines company - Jiangsu Recbio Technology Co., Ltd. ("Recbio" or the "Company", Stock Code: 2179.HK) went public and was officially listed on the Hong Kong Stock Exchange.